To evaluate the efficacy and safety of the anti-tumor necrosis factor alpha monoclonal antibody infliximab in the treatment of active psoriatic arthritis (PsA) resistant to previous symptom modifying antirheumatic drugs.
Efficacy of infliximab in resistant psoriatic arthritis / Salvarani, Carlo; Cantini, Fabrizio; Olivieri, Ignazio; Macchioni, Pierluigi; Padula, Angela; Niccoli, Laura; Catanoso, Maria Grazia; Scocco, Giovanni Lo; Boiardi, Luigi. - In: ARTHRITIS AND RHEUMATISM. - ISSN 0004-3591. - 49:4(2003), pp. 541-545. [10.1002/art.11201]
Efficacy of infliximab in resistant psoriatic arthritis
SALVARANI, CARLO;
2003
Abstract
To evaluate the efficacy and safety of the anti-tumor necrosis factor alpha monoclonal antibody infliximab in the treatment of active psoriatic arthritis (PsA) resistant to previous symptom modifying antirheumatic drugs.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
